Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Clinical trial NCT02037529 · SUSPENDED

Trial details

NCT number: NCT02037529
Sponsor: Academic and Community Cancer Research United
Status: SUSPENDED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Adenocarcinoma HER2/Neu Negative Invasive Breast Carcinoma Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7

Start date: 2014-01-17
Primary completion: 2021-02-11
Enrollment: 201

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.